OncoMatch/Clinical Trials/NCT04234048
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Is NCT04234048 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Fenretinide for t-cell lymphoma.
Treatment: Fenretinide — This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage IB, II, III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: any prior systemic or skin-directed therapy
Relapsed or refractory (R/R) disease, after at least 1 prior treatment regimen as per disease staging (including but not limited to oral bexarotene, interferon, any oral or IV HDAC inhibitor, any topical, oral or IV chemotherapy drugs, radiotherapy, retinoids, topical steroids, systemic steroids, phototherapy, immunomodulators, Biologics and others based on PI discretion)
Cannot have received: fenretinide (fenretinide)
Patients who have received prior fenretinide systemic therapy
Lab requirements
Blood counts
Leukocytes ≥ 3,000/μL; ANC ≥ 1,500/μL; Platelets ≥ 100,000/μL; For bone marrow involved NHL: ANC ≥ 500/μL; Platelets ≥ 50,000/μL
Kidney function
Creatinine clearance ≥60 mL/min/1.73m2 by MDRD equation
Liver function
Total bilirubin within normal institutional limits (≤1.5x ULN eligible); AST (SGOT) and ALT (SGPT) within institutional upper limit of normal
Patients must have normal organ and marrow function as defined below: Leukocytes ≥ 3,000/μL; Absolute neutrophil count ≥ 1,500/μL; Platelets ≥ 100,000/μL; Total bilirubin within normal institutional limits. Patients with total bilirubin ≤ 1.5 X upper limit of normal are eligible; AST (SGOT) and ALT (SGPT) within institutional upper limit of normal; Creatinine clearance ≥60 mL/min/1.73m2 by the Modification of Diet in Renal Disease (MDRD) equation. For bone marrow involved NHL: ANC ≥ 500/μL; Platelets ≥ 50,000/μL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Arizona · Scottsdale, Arizona
- City of Hope Medical Foundation · Duarte, California
- University of Southern California · Los Angeles, California
- University of Colorado Anschutz Medical Campus · Aurora, Colorado
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify